Indaptus Therapeutics, Inc.
29.19%
38,895,000
1857044
Jun 23, 2026
Jun 26, 2026, 09:40 PM
Reporting Persons (2)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Sino Lion Ventures Ltd | CO | 29.19% | 38,895,000 | 0 | 38,895,000 |
| Chenhao Xu | Individual | 29.19% | 38,895,000 | 0 | 38,895,000 |
Disclosure Items (7)
Common Stock, par value $0.01 per share
Indaptus Therapeutics, Inc.
c/o Indaptus Therapeutics, Inc., New York, NY, 10019
This Amendment No. 2 is being jointly filed by Sino Lion Ventures Limited and Chenhao Xu, (each a "Reporting Person" and collectively, the "Reporting Persons") pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Joint Filing Agreement, dated as of June 26, 2026, by and among the Reporting Persons, attached hereto as Exhibit 99.1.
The principal business address of each of the Reporting Persons is Unit 4312, Champion Tower, 3 Garden Road, Central, Hong Kong
The principal business of each Reporting Person is: (1) Sino Lion Ventures Limited: Investment Holding Company; (2) Chenhao Xu: Controlling person of Sino Lion Ventures Limited.
None of the Reporting Persons has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Sino Lion Ventures Limited is organized under the laws of British Virgin Islands. Chenhao Xu is a citizen of the United Kingdom.
The Series AAA Preferred Stock was purchased by the Reporting Persons pursuant to the Securities Purchase Agreement, dated as of March 19, 2026 (the "Purchase Agreement") between David Lazar, Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng. The Purchase Agreement closed on March 23, 2026. Sino Lion Ventures Limited used working capital in the aggregate amount of $3,998,898.44 to fund its purchase.
The information contained on the cover pages to this Schedule 13D is incorporated herein by reference. As of the date hereof, there are 133,242,324 shares of Common Stock outstanding as of June 24, 2026, as calculated based on the Issuer's Form 8-K filed with the SEC on June 24, 2026.
The following table sets forth the number of Common Stock as to which each of the Reporting Person has (i) the sole power to vote or direct the vote, (ii) shared power to vote or to direct the vote, (iii) sole power to dispose or to direct the disposition, or (iv) shared power to dispose or to direct disposition: Reporting Sole Voting Shared Voting Sole Dispositive Shared Dispositive Persons Power Power Power Power Sino Lion Ventures 0.00 38,895,000.00 0.00 38,895,000.00 Limited Chenhao 0.00 38,895,000.00 0.00 38,895,000.00 Xu
The Reporting Persons have not effected any transaction in the shares of Common Stock during the past 60 days.
No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the common stock beneficially owned by the Reporting Persons.
Not applicable.
The information set forth in Item 6 in the Initial Schedule 13D is incorporated herein by reference. The information set forth in Item 3 and Item 4 above is incorporated herein by reference.
Exhibit 99.1: Joint Filing Agreement, dated as of June 26, 2026, by and between Sino Lion Ventures Limited and Chenhao Xu.